公开(公告)号：US4720454A

公开(公告)日：1988-01-19

申请号：US601650

申请日：1984-04-18

Applicant: Perrin C. White ,  Bo Dupont ,  Maria I. New

Inventor： Perrin C. White ,  Bo Dupont ,  Maria I. New

IPC: C12N9/02 ,  C12Q1/68 ,  C12N15/00

CPC classification number: C12N9/0087 ,  C12Q1/6883 ,  C12Q2600/156 ,  C12Q2600/172

Abstract: A cDNA clone is isolated encoding a bovine adrenal cytochrome P-450 specific for steroid 21-hydroxylation (P-450.sub.C21). This plasmid pC21a contains an insert of 520 base pairs. It hybridizes with mRNA encoding P-450.sub.C21. The peptide encoded by the insert is highly homologous to two peptides isolated from porcine P-450.sub.C21 and shows limited homology to the P-450 induced by phenobarbital in rat liver. This probe and its human equivalents can be used to screen in utero i.e. pre-natal as well as post-natal patients for adrenal hyperplasia since it reacts well with human DNA as shown. These probes can also be useful for an industrial fermentation process to produce cortisone in quantity.

Abstract translation: 分离cDNA克隆，其编码对类固醇21-羟基化（P-450C21）特异性的牛肾上腺细胞色素P-450。 该质粒pC21a含有520个碱基对的插入片段。 它与编码P-450C21的mRNA杂交。 由插入片段编码的肽与从猪P-450C21分离的两种肽高度同源，并且与大鼠肝脏中苯巴比妥诱导的P-450显示有限的同源性。 该探针及其人类等同物可用于筛选子宫内，即出生前以及出生后患者的肾上腺增生，因为如图所示，它与人类DNA发生反应良好。 这些探针也可用于工业发酵过程以量产生可的松。

公开(公告)号：US20080227709A1

公开(公告)日：2008-09-18

申请号：US12046874

申请日：2008-03-12

Applicant: Maria Virginia Pascual ,  Jacques F. Banchereau ,  Damien J. Chaussabel ,  Ellen Kaizer ,  Perrin C. White

Inventor： Maria Virginia Pascual ,  Jacques F. Banchereau ,  Damien J. Chaussabel ,  Ellen Kaizer ,  Perrin C. White

IPC: A61K38/00 ,  A61K31/70 ,  C12Q1/68 ,  C12Q1/02 ,  A61P3/10 ,  C40B30/04 ,  G01N33/53

CPC classification number: C12Q1/6883 ,  A61K38/1793 ,  A61K45/06 ,  C12Q1/6837 ,  C12Q2600/158 ,  G01N2333/545 ,  G01N2333/90245 ,  G01N2800/042

Abstract: The present invention includes composition, methods and systems for detecting, evaluating, diagnosis, tracking and treating Type 1 Diabetes by determining the level of expression of one or more genes listed in Table 1 (e.g., interleukin-1β (IL1B), early growth response gene 3 (EGR3), and prostaglandin-endoperoxide synthase 2 (PTGS2)). The present invention also includes compositions and methods for treating a patient in need thereof with a composition having a therapeutically effective amount of one or more IL-1β antagonists sufficient to spare pancreatic beta cells, including an anti-IL-1β receptor and downstream activators.

Abstract translation: 本发明包括通过测定表1中列出的一种或多种基因的表达水平来检测，评估，诊断，追踪和治疗1型糖尿病的组合物，方法和系统（例如，白细胞介素-1β（IL1B），早期生长反应 基因3（EGR3）和前列腺素 - 内切酶合酶2（PTGS2））。 本发明还包括组合物和方法，该组合物和方法用具有治疗有效量的一种或多种足以备用胰β细胞（包括抗IL-1beta受体）和下游活化剂的IL-1β拮抗剂的组合物治疗有需要的患者。